Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)Depreciation ExpenseEBIATGross ProfitLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Oncology Institute (TOI) Accumulated Depreciation & Amortization (2020 - 2025)

Oncology Institute's Accumulated Depreciation & Amortization history spans 6 years, with the latest figure at $6.9 million for Q4 2025.

  • For Q4 2025, Accumulated Depreciation & Amortization rose 10.45% year-over-year to $6.9 million; the TTM value through Dec 2025 reached $6.9 million, up 10.45%, while the annual FY2025 figure was $6.9 million, 10.45% up from the prior year.
  • Accumulated Depreciation & Amortization reached $6.9 million in Q4 2025 per TOI's latest filing, up from $5.3 million in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $6.9 million in Q4 2025 to a low of $777000.0 in Q1 2021.
  • Average Accumulated Depreciation & Amortization over 5 years is $3.3 million, with a median of $3.1 million recorded in 2022.
  • Peak YoY movement for Accumulated Depreciation & Amortization: grew 5.13% in 2021, then surged 33.46% in 2023.
  • A 5-year view of Accumulated Depreciation & Amortization shows it stood at $3.3 million in 2021, then surged by 32.03% to $4.4 million in 2022, then surged by 33.14% to $5.9 million in 2023, then grew by 7.05% to $6.3 million in 2024, then increased by 10.45% to $6.9 million in 2025.
  • Per Business Quant, the three most recent readings for TOI's Accumulated Depreciation & Amortization are $6.9 million (Q4 2025), $5.3 million (Q3 2025), and $3.6 million (Q2 2025).